BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-746@pharmaconomics
DTSTAMP:20260707T030532Z
DTSTART;VALUE=DATE:20260201
DTEND;VALUE=DATE:20260202
SUMMARY:FENC Phase 2 — PEDMARK
DESCRIPTION:Phase 2 trial results for PEDMARK in cisplatin-induced hearing loss are due Feb 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324xex99d1.htm\n\nTrack it: https://pharmaconomics.com/e/746
URL:https://pharmaconomics.com/e/746
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:FENC catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR